2021
High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis
Li P, Yuan J, Ahmed FS, McHenry A, Fu K, Yu G, Cheng H, Xu ML, Rimm DL, Pan Z. High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis. Frontiers In Oncology 2021, 11: 701492. PMID: 34527580, PMCID: PMC8435777, DOI: 10.3389/fonc.2021.701492.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaPD-L1 expressionMantle cell lymphomaKi67 proliferation rateOverall survivalPD-L1Cell lymphomaImmune checkpoint molecule PD-L1Low PD-L1 expressionLarge B-cell lymphomaX-tile softwareHigher Ki67 proliferation rateLog-rank testMCL casesNumber of M1Tissue microarray blocksB-cell lymphomaProliferation rateImmunophenotypic subclassificationInferior OSLow Ki67Better OSPoor OSPrognostic impactInferior prognosis
2014
Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303
Psyrri A, Lee JW, Pectasides E, Vassilakopoulou M, Kosmidis EK, Burtness BA, Rimm DL, Wanebo HJ, Forastiere AA. Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303. Clinical Cancer Research 2014, 20: 3023-3032. PMID: 24700741, PMCID: PMC4049169, DOI: 10.1158/1078-0432.ccr-14-0113.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarboplatinCarcinoma, Squamous CellCetuximabChemoradiotherapyDisease-Free SurvivalDrug Resistance, NeoplasmFemaleFluorescent Antibody TechniqueHead and Neck NeoplasmsHumansInduction ChemotherapyKaplan-Meier EstimateMaleMiddle AgedMitogen-Activated Protein Kinase KinasesPaclitaxelPhosphatidylinositol 3-KinasesPrognosisProportional Hazards ModelsProto-Oncogene Proteins c-aktRas ProteinsSignal TransductionSquamous Cell Carcinoma of Head and NeckTissue Array AnalysisConceptsProgression-free survivalEvent-free survivalPhase II trialOverall survivalII trialTissue microarrayStage III/IV headMultivariable Cox proportional hazards modelsMultivariable Cox regression analysisNeck squamous cell cancerRAS/MAPK/ERKCox proportional hazards modelInsulin-like growth factor 1 receptorLarge prospective studiesCox regression analysisInferior overall survivalKaplan-Meier methodSquamous cell cancerLog-rank testGrowth factor 1 receptorProportional hazards modelPI3K/Akt pathwayFactor 1 receptorPI3K/AktEGF receptor
2013
Effect of PDL-1 expression on prognosis in head and neck squamous cell carcinoma.
Vasilakopoulou M, Velcheti V, Rampias T, Sasaki C, Rimm D, Fountzilas G, Psyrri A. Effect of PDL-1 expression on prognosis in head and neck squamous cell carcinoma. Journal Of Clinical Oncology 2013, 31: 6012-6012. DOI: 10.1200/jco.2013.31.15_suppl.6012.Peer-Reviewed Original ResearchPDL-1 expressionPDL-1Prognostic significanceT cellsMultivariate Cox proportional hazards modelCox proportional hazards modelNeck squamous cell carcinomaDeath-1 receptorFavorable clinical outcomeKaplan-Meier methodInduces tumor regressionSquamous cell carcinomaHNSCC tissue microarrayLog-rank testProportional hazards modelProtein expression levelsImproved DFSEfficacy outcomesImmunotherapeutic approachesClinical outcomesMultivariable analysisEntire cohortCell carcinomaCancer patientsFavorable outcomeHigh Frequency of Putative Ovarian Cancer Stem Cells With CD44/CK19 Coexpression Is Associated With Decreased Progression-Free Intervals In Patients With Recurrent Epithelial Ovarian Cancer
Liu M, Mor G, Cheng H, Xiang X, Hui P, Rutherford T, Yin G, Rimm DL, Holmberg J, Alvero A, Silasi DA. High Frequency of Putative Ovarian Cancer Stem Cells With CD44/CK19 Coexpression Is Associated With Decreased Progression-Free Intervals In Patients With Recurrent Epithelial Ovarian Cancer. Reproductive Sciences 2013, 20: 605-615. PMID: 23171677, PMCID: PMC3635069, DOI: 10.1177/1933719112461183.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnalysis of VarianceBiomarkers, TumorCarcinoma, Ovarian EpithelialDisease ProgressionDisease-Free SurvivalDrug Resistance, NeoplasmFemaleHumansHyaluronan ReceptorsKaplan-Meier EstimateKeratin-19Middle AgedMultivariate AnalysisNeoplasm Recurrence, LocalNeoplasm StagingNeoplasms, Glandular and EpithelialNeoplastic Stem CellsOvarian NeoplasmsProportional Hazards ModelsRetrospective StudiesRisk FactorsTime FactorsTreatment OutcomeConceptsPutative ovarian cancer stem cellsOvarian cancer stem cellsProgression-free intervalCancer stem cellsRecurrent epithelial ovarian cancerShorter disease-free intervalShorter progression-free intervalDisease-free intervalResidual tumor volumeEpithelial ovarian cancerLog-rank testEpithelial ovarian cancer cellsIndependent significant predictorsAdvanced stage EOCOvarian cancer cellsStem cellsMean followObstetrics stageUnivariable analysisClinicopathologic featuresMultivariable analysisRetrospective studyPrognostic valueOvarian cancerTumor volume
2012
Evaluation of the pattern of SOX2 expression in non-small cell lung cancer (NSCLC) and correlation with clinicopathologic (CP) features and prognosis.
Velcheti V, Cheng H, Yao X, Deng Y, Gettinger S, Rimm D. Evaluation of the pattern of SOX2 expression in non-small cell lung cancer (NSCLC) and correlation with clinicopathologic (CP) features and prognosis. Journal Of Clinical Oncology 2012, 30: e21106-e21106. DOI: 10.1200/jco.2012.30.15_suppl.e21106.Peer-Reviewed Original ResearchNon-small cell lung cancerSquamous cell carcinomaSOX2 expressionWorse median overall survivalYale-New Haven HospitalMedian overall survivalMore stage IIIPatras University HospitalKaplan-Meier analysisCell lung cancerLog-rank testHigh SOX2 expressionNew Haven HospitalMore effective markersSOX2 expression levelsOverall survivalCell carcinomaLung cancerUniversity HospitalIndependent cohortKruskal-Wallis testStage IIIBetter outcomesStem cell transcription factorsSurvival analysisPredictors for response to cetuximab in a prospective clinical trial (E2303) of patients with head and neck squamous cell carcinoma (HNSCC).
Psyrri A, Lee J, Pectasides E, Vassilakopoulou M, Burtness B, Rimm D, Wanebo H, Forastiere A. Predictors for response to cetuximab in a prospective clinical trial (E2303) of patients with head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2012, 30: 5576-5576. DOI: 10.1200/jco.2012.30.15_suppl.5576.Peer-Reviewed Original ResearchClinical trialsEastern Cooperative Oncology Group Phase II TrialExact testStage III/IV HNSCCMultivariate Cox proportional hazards modelMultivariate Cox regression analysisERK1/2 levelsNeck squamous cell carcinomaCox proportional hazards modelEpidermal growth factor receptor inhibitorsPhase II clinical trialGrowth factor receptor inhibitorsManagement of HNSCCPhase II trialCox regression analysisKaplan-Meier methodProspective clinical trialsSquamous cell carcinomaLog-rank testAssociation of biomarkersProportional hazards modelFisher's exact testLogistic regression modelsProtein expression levelsWeekly cetuximab